Previous close | 10.000 |
Open | 10.000 |
Bid | 9.200 x N/A |
Ask | 9.210 x N/A |
Day's range | 9.190 - 10.100 |
52-week range | 8.500 - 19.180 |
Volume | |
Avg. volume | 1,066,573 |
Market cap | 6.699B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 27.09 |
EPS (TTM) | 0.340 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 15.83 |
Adicon Holdings Limited (the "Company" or "Adicon"), one of the largest independent clinical laboratory (ICL) service providers listed on the Stock Exchange of Hong Kong (SEHK), has released its interim results for the first half of 2023. As a leading player in delivering ICL services in China, the Company has maintained a robust performance, marked by a significant improvement in profitability.